E. Matyanova

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

A. S. Potapova, V. N. Amirjanova, A. Karateev, 2022, Rheumatology Science and Practice.

[Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].

E. L. Nasonov, A. Gordeev, E. Galushko, 2022, Terapevticheskii arkhiv.

Pregnancy outcomes in patients with rheumatoid arthritis and systemic lupus erythematosus. Part I. Maternal outcomes

N. Kosheleva, E. V. Fedorova, E. Matyanova, 2019, Rheumatology Science and Practice.

Features of clinical manifestations of rheumatoid arthritis in patients after failure of conventional synthetic disease-modifying antirheumatic drugs therapy depending on the signs of central sensitization

A. S. Potapova, V. N. Amirjanova, A. Karateev, 2023, Rheumatology Science and Practice.